Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 1/18/2018 11:45:12 PM - Followers: 152 - Board type: Free - Posts Today: 0

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.





Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#5944  Sticky Note Aurinia is no longer just an LN focused Lunacy aka John Galt 11/02/17 03:34:15 PM
#6377   Well, at least my data is from the biotech_researcher 01/18/18 11:45:12 PM
#6376   be nice he is a clinton democrat, misinformation cervelo 01/18/18 09:13:41 PM
#6375   The list you promised: "....many, many Parma and moosedogger 01/18/18 08:08:14 PM
#6374   And even more specifically with a P-Value of Lunacy aka John Galt 01/18/18 06:18:27 PM
#6373   The more important list would be one that Lunacy aka John Galt 01/18/18 11:11:03 AM
#6372   From FDA: 22 case studies where phase biotech_researcher 01/18/18 05:22:51 AM
#6371   "...I can list many, many Parma and biotechs moosedogger 01/18/18 05:10:49 AM
#6370   BR, How would he know it’s positive if Jesspro 01/17/18 08:27:04 PM
#6369   Well thanks, good to hear that others are trading_cyclist 01/17/18 07:46:05 PM
#6368   I believe they have a much better pipeline Jesspro 01/17/18 07:36:04 PM
#6367   CEO is not privy to the data as biotech_researcher 01/17/18 07:28:54 PM
#6366   I'm in the same boat with equal investments heldnova 01/17/18 07:02:58 PM
#6365   thanks, and yes....shorts including one not so distinguished trading_cyclist 01/17/18 06:52:12 PM
#6364   You are correct. I think the only noise Jesspro 01/17/18 06:34:02 PM
#6363   Sorry, no link. Just a tweet in the ScifiSailor 01/17/18 06:17:21 PM
#6362   Something is clearly cooking. That said, help trading_cyclist 01/17/18 06:03:24 PM
#6361   I like that the management has been very Jesspro 01/17/18 05:47:08 PM
#6360   Ha, we're in the same boat!! trading_cyclist 01/17/18 05:26:42 PM
#6358   Yes, and remember the infamous Bernie tweat that trading_cyclist 01/17/18 05:02:54 PM
#6357   A single comment from that guy(A. Forgidaboutit) almost Jesspro 01/17/18 04:53:10 PM
#6356   Guys, notice the statement? "if p3 trials are Jesspro 01/17/18 04:46:57 PM
#6355   Truly amazing how that single comment sent the trading_cyclist 01/17/18 04:36:04 PM
#6354   over 3 million shares traded on this spike thesaud 01/17/18 03:54:48 PM
#6353   Yes, it is always good old have some biotech_researcher 01/17/18 03:44:47 PM
#6352   it's nice that they're talking about it. It Jesspro 01/17/18 03:42:54 PM
#6351   Jess, it is old news.... Odi Bruckman (@odibro) 1/17/18, 3:11 biotech_researcher 01/17/18 03:35:35 PM
#6350   Sailor, do you have the news link? Jesspro 01/17/18 03:23:22 PM
#6349   Volume coming in INTL 01/17/18 03:06:07 PM
#6348   To answer my own post: per twitter "Dealreporter ScifiSailor 01/17/18 03:03:11 PM
#6347   Anyone hear any news? Up 5%+ in last ScifiSailor 01/17/18 02:59:50 PM
#6345   Jess, sorry, but I can list many, many biotech_researcher 01/17/18 01:18:31 PM
#6344   Kindzal, While waiting for the p3 results is Jesspro 01/17/18 01:14:29 PM
#6343   Kidzal, you are correct. I expect the two biotech_researcher 01/17/18 01:13:56 PM
#6342   Don't get me wrong. I am long AUPH. kindzal 01/17/18 12:34:29 PM
#6341   Jess re "... do you see auph being moosedogger 01/17/18 11:52:16 AM
#6340   IBB Blackrock keeps loading LivingTheDream 01/17/18 10:50:35 AM
#6339   Doesn’t anybody want to liven up this board. Jesspro 01/17/18 09:10:56 AM
#6338   Correct, that’s what the BPs have to digest Jesspro 01/17/18 09:02:36 AM
#6337   Jess, but your original, specific question was if biotech_researcher 01/17/18 08:47:43 AM
#6336   It’s a risk they have to take to Jesspro 01/17/18 08:22:24 AM
#6335   Jess, highly unlikely that an offer for AUPH biotech_researcher 01/17/18 07:26:33 AM
#6334   Moose, do you see auph being acquired in Jesspro 01/16/18 10:59:54 AM
#6333   "There is something new?" moosedogger 01/16/18 09:57:58 AM
#6332   There is something new? axelvento 01/16/18 08:06:26 AM
#6331   "A lot of FUD today..." moosedogger 01/15/18 11:18:33 AM
#6330   A lot of FUD today... Lunacy aka John Galt 01/15/18 09:51:08 AM
#6329   If approved it will be for LN there LivingTheDream 01/15/18 09:31:24 AM
#6328   This is what will make approval of the biotech_researcher 01/15/18 07:44:23 AM
#6327   An old article but still a good read Jesspro 01/15/18 07:05:09 AM
#6326   Not the p3 trial but the p2 trial. Jesspro 01/14/18 07:18:18 PM